All Updates

All Updates

icon
Filter
Funding
Myricx Bio raises GBP 90 million in Series A funding to develop ADC platform and progress NMTi-ADC pipeline
Precision Medicine
Jul 8, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jul 8, 2024

Myricx Bio raises GBP 90 million in Series A funding to develop ADC platform and progress NMTi-ADC pipeline

Funding

  • Myricx Bio has secured USD GBP 90 million (~USD 115.3 million) in a Series A funding round led jointly by Novo Holdings and Abingworth, with participation from Eli Lilly, Cancer Research Horizons, British Patient Capital, Sofinnova Partners, and Brandon Capital.

  • The funds are planned to be directed toward expanding Myricx’s proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and progressing its pipeline of NMTi-ADCs to the proof-of-concept stage. 

  • UK-based Myricx Bio specializes in discovering and developing a novel class of selective cytotoxic payloads for antibody-drug conjugates (ADCs). The company's proprietary ADCs are claimed to have shown preclinical efficacy and safety across various solid tumor-associated antigens and specific cancer cell types. Myricx Bio is currently focused on developing and refining its NMTi ADC platform to progress its operations into the clinical stage.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.